Anaptysbio (ANAB) Revenue (2016 - 2026)
Anaptysbio's (ANAB) quarterly Revenue came in at $25.6 million in Q1 2026, down 7.98% YoY from $27.8 million in Q1 2025, and down 65.93% on a QoQ basis from $75.0 million in Q4 2025.
Anaptysbio (ANAB) Revenue (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Revenue data on file, last reported at $25.6 million in Q1 2026.
- Quarterly Revenue fell 7.98% year-over-year to $25.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $172.8 million (up 119.47% YoY) and the FY2025 annual result came in at $234.6 million, up 157.01% from the prior year.
- Revenue fell to $25.6 million in Q1 2026, from $75.0 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $75.0 million in Q4 2025 to a low of $970000.0 in Q1 2022.
- A 5-year average of $16.7 million and a median of $9.0 million in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue sank 93.92% — and 2024, when it surged 422.49%.
- Tracing ANAB's Revenue over 5 years: stood at $5.0 million in 2022, then soared by 80.1% to $9.0 million in 2023, then jumped by 177.62% to $25.0 million in 2024, then surged by 200.0% to $75.0 million in 2025, then sank by 65.93% to $25.6 million in 2026.
- The last three Revenue figures came in at $25.6 million (Q1 2026), $75.0 million (Q4 2025), and $50.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | 25.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.56 Mn |
| Dec 31, 2025 | 75.00 Mn |
| Sep 30, 2025 | 50.00 Mn |
| Jun 30, 2025 | 22.26 Mn |
| Mar 31, 2025 | 27.77 Mn |
| Dec 31, 2024 | 25.00 Mn |
| Sep 30, 2024 | 15.00 Mn |
| Jun 30, 2024 | 10.97 Mn |
| Mar 31, 2024 | 7.18 Mn |
| Dec 31, 2023 | 9.01 Mn |
| Sep 30, 2023 | 3.32 Mn |
| Jun 30, 2023 | 3.46 Mn |
| Mar 31, 2023 | 1.37 Mn |
| Dec 31, 2022 | 5.00 Mn |
| Sep 30, 2022 | 1.29 Mn |
| Jun 30, 2022 | 1.22 Mn |
| Mar 31, 2022 | 970,000.00 |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | 20.00 Mn |
| Jun 30, 2021 | 20.00 Mn |